Head to head
Zinc-L-carnosine against Larazotide
Two gut barrier compounds that both went through a regulator, with different endings. Zinc-L-carnosine has been a prescription gastric medicine in Japan since 1994 and has a positive randomised phase 3; larazotide's phase 3 did not meet its primary endpoint.
Column A
Zinc-L-carnosineZinc-L-carnosine (polaprezinc), zinc and carnosine chelate
A zinc and dipeptide chelate approved as a gastric drug in Japan, with a randomised phase 3 showing it prevented radiotherapy-induced swallowing difficulty in breast cancer patients.
Column B
LarazotideLarazotide Acetate (AT-1001)
An investigational gut-barrier peptide for celiac disease that reached Phase 3 but was terminated by the sponsor without a published result.
Side by side, on the facts we can check
| Attribute | Zinc-L-carnosine | Larazotide |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| FDA status | Not an FDA-approved drug. Sold as a dietary supplement in the United States. Approved as a prescription gastric medicine in Japan, where it has been marketed since 1994. | Investigational; Phase 3 did not meet primary endpoint |
| Half-life | Not meaningfully described as a chelate, because its intended action is local adhesion to mucosa and local zinc release rather than systemic exposure. | Short (acts locally in the gut) |
| Molecular weight | Roughly 289 Da for the zinc and L-carnosine complex. | ~732 Da |
| Mechanism | A one-to-one chelate of zinc and L-carnosine. The chelate adheres preferentially to ulcerated and inflamed mucosal surfaces, where it dissociates and releases zinc locally at higher concentration than systemic zinc dosing would achieve. Zinc contributes to epithelial repair, membrane stabilisation and antioxidant defence through metallothionein induction, and carnosine has direct antioxidant and metal-chelating activity. In cell and animal work it accelerates epithelial migration and restitution, and it raises heat shock protein expression. Note that its actions are largely local to mucosa, which is why the evidence concerns gut and mucosal injury rather than systemic outcomes. | Antagonizes zonulin signaling to strengthen intestinal tight junctions and limit passage of gluten fragments across the gut lining. |
| Human studies cited | 1 | 3 |
| Legal status, US | Sold as a supplement | Investigational, not approved |
Frequently asked questions
What is the difference between Zinc-L-carnosine and Larazotide?
Zinc-L-carnosine: A zinc and dipeptide chelate approved as a gastric drug in Japan, with a randomised phase 3 showing it prevented radiotherapy-induced swallowing difficulty in breast cancer patients. Larazotide: An investigational gut-barrier peptide for celiac disease that reached Phase 3 but was terminated by the sponsor without a published result.
Which has stronger research evidence, Zinc-L-carnosine or Larazotide?
This database does not grade compounds. It counts what was run in people: 1 of the 1 studies cited on the Zinc-L-carnosine profile were human work, against 3 of 3 for Larazotide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Zinc-L-carnosine and Larazotide FDA-approved?
Zinc-L-carnosine: Not an FDA-approved drug. Sold as a dietary supplement in the United States. Approved as a prescription gastric medicine in Japan, where it has been marketed since 1994.. Larazotide: Investigational; Phase 3 did not meet primary endpoint.
Related posts
Blog articles that cover Zinc-L-carnosine or Larazotide, newest first.
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.